"Marxisme et philosophie du langage" (1929) de V. Volochinov et sa réception chez R. Chor : deux voies du développement de la science du langage «marxiste» dans les années 1920 en Russie

Malgré le succès de  « Marxisme et philosophie du langage » (par la suite MPL) de V. Volochinov, ce texte n'a suscité que trois comptes rendus. Le quatrième est ébauché par A. Romm. Resté à l'état de notes, ce compte rendu est bien étudié par les chercheurs contemporains. En revanche, le compte rendu écrit par R. Chor n'a jamais été analysé de façon détaillée. Notre article a pour but de combler cette lacune et porte sur le contenu de l'analyse critique de MPL faite par Chor. Son examen révèle que le compte rendu écrit par cette dernière et MPL de Volochinov représentent la formulation de principes de base diamétralement opposés de la science du langage «marxiste». Cela se manifeste dans la réception des idées de F. de Saussure. Si Chor considère la conception de ce dernier comme fondement de la linguistique «théorique» portant sur la langue en tant que système de signes (ou de «signifiances» dans les termes de Chor), Volochinov rejette la théorie de Saussure. Il la considère comme «abstraite», d'où le nom «objectivisme abstrait» qu'il donne au saussurisme. En élaborant la philosophie du langage «marxiste», il s'appuie sur la néo-philologie idéaliste (les idées de Vossler et de son Ecole) définie dans MPL comme «subjectivisme individualiste». Volochinov propose d'étudier la «langue» comme fait réel, accessible à l'observation immédiate et non pas comme objet d'étude «théorique». Ce fait constitue une cible de la critique adressée par Chor à Volochinov

Suurlähettiläs R.R. Seppälä 20/1 1962

Kirje

Demand for pharmaceutical drugs: A choice modelling experiment

Despite the importance of supplier inducement and brand loyalty inthe drug purchasing process, little empirical evidence is to be foundwith regard to the influence that these factors exert on patients decisions. Under the new scenario of easier access to information,patients are becoming more demanding and even go as far asquestioning their physicians prescription. Furthermore, newregulation also encourages patients to adopt an active role in thedecision between brand-name and generic drugs. Using a statedpreference model based on a choice survey, I have found evidenceof how significant physicians prescription and pharmacists recommendation become throughout the drug purchase process and,to what extent, brand loyalty influences the final decision. Asfar as we are aware, this paper is the first to explicitlytake consumers preferences into account rather than focusingon the behavior of health professionals.

R&D cooperation and spillovers: Some empirical evidence

This paper provides some first empirical evidence on the relationshipbetween R&D spillovers and R&D cooperation. The results suggest disentangling different aspects of know-how flows. Firms which rate incoming spillovers more importantly and who can limit outgoing spillovers by a more effective protection of know-how, are more likely to cooperate in R&D. Our analysis also finds that cooperating firms have higher incoming spillovers and higher protection of know-how, indicating that cooperation may serve as a vehicle to manage information flows. Our results thus suggest that on the one hand the information sharing and coordination aspects of incoming spillovers are crucial in understanding cooperation, while on the other hand, protection against outgoing spillovers is important for firms to engage in stable cooperative agreements by reducing free-rider problems. Distinguishing different types of cooperative partners reveals that while managing outgoing spillovers is less critical in alliances with non-commercial research partners than between vertically related partners, the incoming spillovers seem to be more critical in understanding the former type of R&D cooperation.

Patentes, regulación de precios e innovación en la industria farmacéutica

The trade-off between property rights/price regulation and innovation depends on countrycharacteristics and drug industry specificities. Access to drugs and innovation can bereconciled by seven ways that, among others, include: public health strengthening in thecountries with the largest access problems (those among the poor with the weakestinstitutions); public and private aid to make attractive R&D on neglected diseases; pricediscrimination with market segmentation; to require patent owners to choose eitherprotection in the rich countries or protection in the poor countries (but not both).Regarding price regulation, after a review of theoretical arguments and empirical evidence,seven strategies to reconcile health and industrial considerations are outlined, including:mitigation of the medical profession dependence on the pharmaceutical industry; considerationof a drug as an input of a production process; split drug authorization from public fundingdecisions; establish an efficiency minimum for all health production inputs; and stop theEuropean R&D hemorrhagia.

Suurlähettiläs R.R. Seppälä 13/1 1967

Kirje

Tal vid sibeliusveckans öppningshögtidlighet år 1955

Puhe

Hybrid risk adjustment for pharmaceutical benefits

This paper analyses the application of hybrid risk adjustment versus either prospective orconcurrent risk adjustment formulae in the context of funding pharmaceutical benefits for thepopulation of an integrated healthcare delivery organization in Catalonia during years 2002 and2003. We apply a mixed formula and find that a hybrid risk adjustment model increasesincentives for efficiency in the provision of low risk individuals at health organizations not only asa whole but also at each internal department compared to only prospective models by reducingwithin-group variation of drug expenditures.

External morphology of the immature stages of Neotropical heliconians: IX. Dione glycera (C. Felder & R. Felder) (Lepidoptera, Nymphalidae, Heliconiinae)

External morphology of the immature stages of Neotropical heliconians: IX. Dione glycera (C. Felder & R. Felder) (Lepidoptera, Nymphalidae, Heliconiinae). The biology of the Andean silverspot butterfly Dione glycera (C. Felder & R. Felder, 1861) is still poorly known. This species is restricted to high elevations in the Andes, where the immature stages are found in close association with species of Passiflora belonging to the section Tacsonia (Juss.) Harms, especially P. tripartida var. mollissima (Kunth), which is grown for subsistence by villagers. Herein we describe and illustrate the external features of the egg, larva and pupa of D. glycera, based on light and scanning electron microscopy.